Alvotech is a privately owned biopharmaceutical company focused on the development and manufacturing of high quality biosimilars for global markets. We are specialists in biotechnology all working towards a common goal: to be a global leader in the biosimilar space.
We are focused on developing and bringing to market highest quality biosimilars. Our pipeline consists of seven biosimilar monoclonal antibodies aimed at treating cancer, autoimmune, inflammatory and other diseases.
Our organizational structure is effective, flexible and has a proven track record that will enable the company to bring new biopharmaceutical products quickly and safely to market. The leadership team is helmed by Rasmus Rojkjaer.